What is GlaxoSmithKline Consumer Nigeria Sloan Ratio %?
Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
As of Jun. 2023, GlaxoSmithKline Consumer Nigeria has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.
GlaxoSmithKline Consumer Nigeria Sloan Ratio % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
GlaxoSmithKline Consumer Nigeria Sloan Ratio % Chart
Competitive Comparison of GlaxoSmithKline Consumer Nigeria's Sloan Ratio %
For the Drug Manufacturers - General subindustry, GlaxoSmithKline Consumer Nigeria's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GlaxoSmithKline Consumer Nigeria's Sloan Ratio % Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Consumer Nigeria's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where GlaxoSmithKline Consumer Nigeria's Sloan Ratio % falls into.
GlaxoSmithKline Consumer Nigeria Sloan Ratio % Calculation
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
GlaxoSmithKline Consumer Nigeria's Net Income for the trailing twelve months (TTM) ended in Jun. 2023 was 154.983 (Jun. 2022 ) + 134.193 (Sep. 2022 ) + 287.603 (Dec. 2022 ) + 184.551 (Jun. 2023 ) = ₦761 Mil.
GlaxoSmithKline Consumer Nigeria's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2023 was 1761.712 (Jun. 2022 ) + 5242.766 (Sep. 2022 ) + 1585.669 (Dec. 2022 ) + 0 (Jun. 2023 ) = ₦8,590 Mil.
GlaxoSmithKline Consumer Nigeria's Cash Flow from Investing for the trailing twelve months (TTM) ended in Jun. 2023 was 69.906 (Jun. 2022 ) + 76.038 (Sep. 2022 ) + 280.903 (Dec. 2022 ) + 0 (Jun. 2023 ) = ₦427 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GlaxoSmithKline Consumer Nigeria (NSA:GLAXOSMITH) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Jun. 2023, GlaxoSmithKline Consumer Nigeria has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.
GlaxoSmithKline Consumer Nigeria Sloan Ratio % Related Terms
Thank you for viewing the detailed overview of GlaxoSmithKline Consumer Nigeria's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.
GlaxoSmithKline Consumer Nigeria (NSA:GLAXOSMITH) Business Description
GlaxoSmithKline Consumer Nigeria PLC is a healthcare company that researches, develops, and manufactures pharmaceutical medicines, vaccines, and consumer healthcare products. The company has two reportable segments, the Consumer Healthcare segment consisting of oral care, over-the-counter (OTC) medicines, and nutritional healthcare; and the Pharmaceuticals segment consisting of vaccines and prescription drugs. The company's product line includes panadol, Andrews liver salt, Macleans, ampiclox, Sensodyne, and others. The generates maximum revenue from the Pharmaceuticals segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NSA:GLAXOSMITH has been successfully added to your 